What is the recommended dose of Toradol (Ketorolac) for pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ketorolac Dosing for Pediatric Patients

For pediatric patients, the recommended intravenous dose of ketorolac is 0.5 mg/kg as a single bolus, followed by either 1.0 mg/kg every 6 hours or a continuous infusion of 0.17 mg/kg/hour, with a maximum daily dose of 90 mg and treatment duration not exceeding 48 hours. 1

Age and Weight Considerations

  • Ketorolac is not recommended for infants under 1 year of age 1
  • For children aged 4-8 years receiving a single 0.5 mg/kg IV bolus, the elimination half-life is approximately 5.8 hours, with higher volume of distribution and clearance compared to adults 2
  • Older children may require somewhat lower dosages, while infants and young children may require slightly higher dosages to achieve equivalent pain relief 1

Route of Administration

  • The intravenous route is strongly preferred during the immediate postoperative period until the patient can tolerate oral medication 1
  • Intramuscular injections are not recommended in children unless the intravenous route is unavailable 1
  • For oral administration when appropriate, the recommended dose is 0.25 mg/kg up to a maximum of 1.0 mg/kg/day, with treatment not exceeding 7 days 1

Dosing Ceiling Effect in Larger Pediatric Patients

  • For pediatric patients weighing at least 60 kg, a maximum dose of 15 mg IV ketorolac provides effective analgesia comparable to 30 mg, demonstrating a ceiling effect similar to adults 3
  • This lower maximum dose (15 mg versus 30 mg) resulted in effective pain control with mean pain score reductions of 5.1 versus 3.9 on a 10-point scale 3

Pharmacokinetic Differences from Adults

The pharmacokinetics of ketorolac differ significantly in pediatric patients:

  • Volume of distribution is increased by up to 2-fold compared to adults 1
  • Plasma clearance is higher in children, likely due to lower plasma protein binding 1
  • Despite these differences, the elimination half-life remains similar between children and adults (approximately 5-6 hours) 1
  • These pharmacokinetic differences necessitate higher relative dosing in children, though dosing intervals remain similar to adults 1

Maximum Dosing Limits

  • Absolute maximum daily dose: 90 mg 1
  • Maximum treatment duration: 48 hours for IV administration 1
  • Maximum treatment duration: 7 days for oral administration 1

Clinical Efficacy

  • Ketorolac demonstrates analgesic efficacy equivalent to major opioid analgesics such as morphine and superior to codeine for postoperative pain in children 1
  • When combined with opioids, ketorolac exhibits marked opioid-sparing effects, allowing lower opioid doses and reducing opioid-related adverse effects including respiratory depression, nausea/vomiting, and ileus 1

Safety Considerations and Contraindications

Important caveats:

  • Controversy exists regarding ketorolac use after tonsillectomy due to potential increased risk of postoperative hemorrhage 1
  • For other pediatric surgeries, multiple studies confirm ketorolac is not associated with increased bleeding risk 1
  • Bleeding time may be slightly increased but typically remains within normal values due to reversible antiplatelet effects 1
  • Unlike opioids, ketorolac does not cause respiratory depression, sedation, nausea/vomiting, or urinary retention 1

Adult Dosing for Reference (Not Pediatric)

The adult guideline from 2002 lists 60 mg IM every 15-30 minutes with a maximum of 120 mg per day for migraine treatment, but this is not applicable to pediatric dosing 4

References

Research

Ketorolac Dose Ceiling Effect for Pediatric Headache in the Emergency Department.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2024

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.